U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the

Press/Media: Press / Media

PeriodOct 30 2018

Media coverage

2

Media coverage

  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the
    Media name/outletPR Newswire
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the
    Media name/outletPR Newswire
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo